Table 4 Relationships between IQR increases in estimated intercepts and slopes of exposure across in utero development and hormone levels at 8–14 years (n = 104)^a

BPA^b

Intercept

−3.6 (−13.6, 7.5)

12.8 (−16, 51.6)

2.3 (−8.8, 14.9)

−0.9 (−15.1, 15.7)

5.7 (−6.1, 18.9)

Slope

n/a

n/a

n/a

n/a

n/a

MBzP^b

Intercept

6.1 (−4.5, 17.9)

20.4 (−9.5, 60.1)

9.8 (−1.7, 22.6)

−5.4 (−18.5, 9.9)

1.5 (−9.6, 13.8)

Slope

n/a

n/a

n/a

n/a

n/a

MCPP

Intercept

8.3 (−5.3, 24.0)

9.4 (−24.2, 57.8)

15.3 (0.3, 32.6)*

−7.1 (−23.2, 12.5)

5.6 (−8.7, 22.3)

Slope

2.7 (−9.7, 16.9)

−0.5 (−30.0, 41.3)

14.5 (0.2, 30.9)*

−7.3 (−22.8, 11.4)

−1.4 (−14.3, 13.3)

MEP

Intercept

−6.3 (−17.2, 6.1)

6.7 (−23.5, 48.8)

4.9 (−8.1, 19.7)

−6.7 (−21.8, 11.3)

−6.8 (−18.3, 6.4)

Slope

−7.4 (−16.8, 3.1)

−22.1 (−41.6, 3.8)

0.0 (−10.8, 12.1)

−4.8 (−18.3, 10.9)

−12.9 (−22.3, −2.4)*

ΣDEHP

Intercept

15.0 (3.2, 28.2)*

6.2 (−21.6, 43.9)

9.4 (−2.8, 23.0)

0.4 (−14.4, 17.7)

6.6 (−5.4, 20.2)

Slope

0.9 (−9.7, 12.8)

−9.1 (−33.3, 24.0)

9.2 (−3.2, 23.0)

−2.2 (−16.8, 15.1)

−6.6 (−17.3, 5.6)

ΣDBP

Intercept

8.7 (−7.0, 27.1)

−12.4 (−42.6, 33.7)

11.2 (−5.7, 31.1)

−14.9 (−31.7, 5.9)

5.1 (−11.3, 24.5)

Slope

0.7 (−12.1, 15.2)

−19.8 (−44.4, 15.7)

10.5 (−4.2, 27.4)

−14.4 (−29.2, 3.6)

−2.7 (−15.9, 12.7)